Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed through tissue testing with locally advanced or spreading lung cancer (stage IIIB–IV) that shows certain abnormal neuroendocrine features — specifically, at least one positive marker (CD56, CgA, or Syn) on a special staining test, but without the typical neuroendocrine tumour appearance under a microscope.
- People who have at least one tumour that can be measured on a scan, according to a standard measurement system called RECIST v1.1.
- People who have a general health and activity level rated 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity.
- People whose doctor has determined them suitable for first-line single-agent immunotherapy, or whose cancer has come back or progressed after standard first-line treatment.
- People whose urine protein levels are below a certain threshold — either less than "++" on a urine dipstick test, or if "++" or higher, a 24-hour urine protein measurement of no more than 1.0g.
- People whose expected survival time is greater than 3 months.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have been diagnosed with a pulmonary neuroendocrine tumour, including typical carcinoid, atypical carcinoid, small cell carcinoma, or large cell neuroendocrine carcinoma.
- People who have previously received anti-VEGF or anti-VEGFR targeted therapy, or any anti-PD-1 or anti-PD-L1 immunotherapy.
- People who have uncontrolled high blood pressure (systolic above 150 mmHg or diastolic above 90 mmHg) even while taking blood pressure medication.
- People who have an active stomach or intestinal ulcer, a hole in the intestine (perforation), or a blockage in the intestine.
- People who have active bleeding or a tendency to bleed.
- People who have a serious history of heart or blood vessel disease affecting the heart or brain.
- People who have been diagnosed with another cancer within the past 5 years — except for certain skin cancers (basal cell carcinoma) or early-stage cervical cancer that have been fully removed by surgery.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Puyuan Xing, Doctorate, Department of Medical Oncology, National Cancer Center, China
Phone: +86-10-87787421
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.